Participants reported that digitally delivered therapies offered similar effectiveness to in-person treatments, improved access to care, and unique advantages such as cost-effectiveness and efficient resource use.
The standard dose of ketamine significantly reduced PTSD symptoms after the first infusion, while the low dose showed significant symptom reduction after the last infusion and at the 4-week follow-up. The standard dose also significantly ameliorated depression symptoms.
The meta-analysis indicated that ketamine did not increase the prevalence of PTSD and showed significant improvements in PTSD scales for chronic patients, with a mean difference of -3.66 (95% CI: -7.05 to -0.27, p = 0.03) in chronic cases. Short-term PTSD patients did not show the same level of benefit.
Significant reductions in anxiety, depression, and PTSD symptoms were observed, with effect sizes ranging from 0.75 to 0.86 at 3 months and sustained effects at 6 months. 50-75% of participants reported clinically meaningful improvements at 3 months, and 48-70% at 6 months.
The study found that MDMA-AT correlated with increased functional connectivity between the amygdala and hippocampus, and reduced activation in brain regions associated with trauma processing. Patients showed significant recovery from PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (CAPS-IV).
MDMA-AP significantly improves symptoms of dissociation, depression, and functional impairment in patients with PTSD compared to control groups. The treatment has shown long-lasting effects and is particularly beneficial for those who do not respond to traditional SSRI treatments.
High retention rate of 80% for participants who completed all therapy sessions, indicating acceptability and feasibility of NET in this population. Participants engaged well with the therapy once initiated.
The study found substantial reductions in PTSD symptoms among veterans treated with ART, with large effect sizes observed in PTSD scores across different groups, including those with prior unsuccessful treatments. The treatment completion rate was 72%, indicating a favorable response to ART.
Both groups showed improvement in PTSD symptoms at post-ECT and 3-month follow-up, with large effect sizes observed for all outcomes, indicating the efficacy of ECT in treating PTSD with comorbid depression.
Overall, PTSD symptoms decreased from pre-intervention through follow-up across all conditions, with TF-CBT and CCT showing relative benefits over TAU. Cortical activation patterns were significantly correlated with improvements in PTSD symptoms, indicating that neuroimaging could be a useful tool for predicting treatment response.
Participants showed improved emotional processing, reduced PTSD and BPD symptoms, and enhanced mood following Amygdala up-modulation training. The study indicates that Amygdala self-modulation can be learned and may modify brain functionality.
fMRI-guided rTMS resulted in over 60% improvement in depression and PTSD symptoms, with durable effects observed at 6-month follow-up.
The review identified preliminary evidence that alternative pharmacological agents can normalize brain function in PTSD patients, particularly through the use of oxytocin, which improved functional connectivity and brain region activity related to emotion and cognition.
Patients with PTSD showed altered brain activation patterns, with lower hippocampal activity during unpredictable contexts and higher amygdala activity during predictable contexts, indicating differences in fear processing compared to controls.
The study found significant differential methylation near 195 genes associated with PTSD, implicating DNA methylation as a key mechanism in the disorder's pathophysiology. It also identified 6,641 candidate genes and specific changes in ketamine responders, suggesting potential pathways for therapeutic intervention.
The findings indicate that SOC strategies, when combined with high levels of perceived social support and life satisfaction, significantly reduce PTSD symptoms among elderly individuals. The study highlights the moderating effect of age groups on the SOC-PTSD relationship, suggesting that tailored interventions can enhance mental health outcomes for seniors.
All therapies produced large effects compared to passive control conditions at post-treatment. TF-CBT and EMDR yielded medium treatment effects compared to active control conditions, while other-TF-PIs and non-TF-PIs yielded small treatment effects. The interventions were found to be effective and acceptable for treating adult PTSD.
The study found that 38.8% of patients in the Aleozen group developed PTSD after 90 days, compared to 61.2% in the placebo group, demonstrating a statistically significant reduction in PTSD incidence (p<0.001).
The network meta-analysis found that TF-CBT, EMDR, MDTs, and non-trauma-focused interventions were all effective in reducing PTSD symptoms compared to passive control conditions, with large pooled effect sizes. TF-CBT consistently showed the highest treatment effects, particularly for multiple-event-related PTSD, indicating its strong efficacy in both short-term and long-term outcomes.
The findings concluded that there were no major or recurrent intervention-associated DNA methylation changes in the investigated genes in monocytes of patients with PTSD or AN, suggesting that psychotherapy did not significantly alter the epigenetic markers in these populations.
Participants in dance therapy reported improved emotional expression, better management of psychopathological symptoms, and a sense of security and flow during sessions, leading to reduced trauma symptoms and enhanced interpersonal relationships.
Most responders experienced clinical improvement after an average of 8.88 years, with a modest decline in symptom burden observed by 2022.
Significant reduction in psychological distress, improvements in mental health symptoms, increased physical activity, reduced sedentary time, and enhanced quality of life were observed. Retention in the study was high at 92%.
The findings indicate that addressing PTSD symptoms can lead to improvements in internalizing symptoms and social functioning, suggesting a need for targeted interventions.
Clinical response was observed in both depression and PTSD symptoms, with a depression response rate of 45.5% and remission rate of 22.7%. PTSD response rate was also 45.5%, with an 18.2% remission rate. The occurrence of flashbacks did not hinder clinical response when managed appropriately.
Positive treatment effects were observed for early interventions using conventional trauma-focused therapies and psychological counseling, which may help alleviate symptoms of CB-PTSD and improve maternal health outcomes. However, the effectiveness of these therapies as tertiary interventions is uncertain.
Participants showed significant improvements in depressive symptoms and perceived stress, particularly in those with a history of MST, and medium to large treatment effects were noted in Veterans with histories of suicidal ideation or attempts.
The study identifies stable cross-species PTSD phenotypes related to impaired neutral learning/memory and fear extinction, which could be targeted for new treatments. Enhanced understanding of emotional memory discrepancies between clinical and preclinical studies is also a positive outcome.
The review highlighted the need for well-designed trials to better understand effective treatments for PTSD in vulnerably housed populations, emphasizing the importance of trauma-informed care in improving treatment engagement and outcomes.